AMENDMENT NO. 3
[*] indicates confidential portions omitted pursuant to a request for confidential treatment filed
separately with the Securities and Exchange Commission
2
3
4
5
6
Bank Credit Agreement | Term Loan Credit Agreement | |||||
Schedule 2.01
|
Revolving Commitments and Commitment Percentages | Schedule 2.01 | Term Loan Commitments and Commitment Percentages (Tranche A Term Loan Only) | |||
Schedule 8.01
|
Existing Indebtedness | Schedule 8.01 | Existing Indebtedness | |||
Schedule 8.02
|
Existing Liens | Schedule 8.02 | Existing Liens | |||
Schedule 8.03
|
Existing Investments | Schedule 8.03 | Existing Investments | |||
Schedule 8.06
|
Restricted Payments | Schedule 8.06 | Restricted Payments | |||
Exhibit 7.02
|
Form of Compliance Certificate | Exhibit 7.02 | Form of Compliance Certificate |
APPLICABLE PERCENTAGES FOR REVOLVING LOANS AND LETTERS OF CREDIT | ||||||||
Eurocurrency Rate |
||||||||
Pricing |
Consolidated |
Loans and Standby |
Base Rate |
Commitment |
||||
Level | Leverage Ratio | Letters of Credit | Loans | Fee | ||||
I
|
£ 2.0:1.0 | 1.375% | 0.375% | 0.500% | ||||
II
|
> 2.0:1.0 but £ 2.5:1.0 | 1.500% | 0.500% | 0.500% | ||||
III
|
> 2.5:1.0 | 1.625% | 0.625% | 0.500% |
7
APPLICABLE PERCENTAGES FOR TRANCHE A TERM LOAN | ||||||
Pricing |
Eurocurrency Rate |
|||||
Level | Consolidated Leverage Ratio | Loans | Base Rate Loans | |||
I
|
£ 2.0:1.0 | 1.375% | 0.375% | |||
II
|
> 2.0:1.0 but £ 2.5:1.0 | 1.500% | 0.500% | |||
III
|
> 2.5:1.0 | 1.625% | 0.625% |
Remaining Principal |
Total Principal Balance |
|||
Balance of Tranche A |
Incremental |
of Tranche A Term Loan |
||
Term Loan | Tranche A Term Loan | After Incremental | ||
$1,314,556,962.00
|
$50,443,038.00 | $1,365,000,000.00 |
8
9
10
11
12
FRESENIUS MEDICAL CARE AG & Co. KGaA, a German partnership limited by shares, represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, a German corporation, its general partner | ||
By:
/s/ Xx. Xxxxxxxx
Xxxxx Xxxx: Xx. Xxxxxxxx
Xxxxx
Title: Member of the Management Board |
||
By:
/s/ Xxxx
Xxxxxx Xxxx: Xxxx
Xxxxxx
Title: Member of the Management Board |
13
BORROWER AND GUARANTOR:
|
FRESENIUS MEDICAL CARE NORTH AMERICA HOLDINGS LIMITED PARTNERSHIP, a Delaware limited partnership | |
By: Fresenius Medical Care US Vermögensverwaltungs
GmbH and Co. KG, a German partnership
|
||
Its General Partner | ||
By: Fresenius Medical Care
Vermögensverwaltungs GmbH, a German limited liability company |
||
Its General Partner | ||
By:
/s/ Xxxxx
Xxxxxx Xxxx: Xxxxx
Xxxxxx
Title: Managing Director |
14
BORROWERS AND GUARANTORS:
|
FRESENIUS MEDICAL CARE HOLDINGS, INC., a New York corporation | |
By:
/s/ Xxxx
Xxxxxxx Xxxx: Xxxx
Xxxxxxx
Title: Vice President and Assistant Treasurer |
15
By: |
/s/ Xxxx
Xxxxxxx
|
Title: Vice President and Treasurer
16
GUARANTORS:
|
BIO-MEDICAL APPLICATIONS OF MARYLAND, INC., a Delaware
corporation FRESENIUS SECURITIES, INC., a California corporation SRC HOLDING COMPANY, INC., a Delaware corporation |
|
By:
/s/ Xxxx
Xxxxxxx Xxxx: Xxxx
Xxxxxxx
Title: Vice President and Treasurer |
17
GUARANTORS:
|
BIO-MEDICAL APPLICATIONS MANAGEMENT COMPANY, INC., a
Delaware corporation NMC A, LLC, a Delaware limited liability company BIO-MEDICAL APPLICATIONS OF MAINE, INC., a Delaware corporation EVEREST HEALTHCARE HOLDINGS, INC, a Delaware corporation FRESENIUS MANAGEMENT SERVICES, INC, a Delaware corporation RENAL CARE GROUP, INC., a Delaware corporation DIALYSIS CENTERS OF AMERICA — ILLINOIS, INC., an Illinois corporation STAT DIALYSIS CORPORATION, a Delaware corporation RENAL CARE GROUP OF THE MIDWEST, INC., a Kansas corporation |
|
By:
/s/ Xxxx
Xxxxxxx Xxxx: Xxxx
Xxxxxxx
Title: Vice President and Treasurer |
||
NEW YORK DIALYSIS SERVICES, INC., a New York corporation | ||
By:
/s/ Xxxx
Xxxxxxx Xxxx: Xxxx
Xxxxxxx
Title: Treasurer |
18
GUARANTORS:
|
NATIONAL MEDICAL CARE OF SPAIN, S.A., a corporation (sociedad anónima) organized under the laws of Spain | |
By:
/s/ Dr. Xxxxxx
Xxxxxxx Xxxx: Dr. Xxxxxx
Xxxxxxx
Title: Authorized Representative |
19
GUARANTORS:
|
FMC TRUST FINANCE S.à x.x. LUXEMBOURG-III, a private limited company (société à responsabilité limitée) organized under the laws of Luxembourg | |
By:
/s/ Xxxxxxxx
Xxx Xxxx: Xxxxxxxx
Xxx
Title: Manager |
||
FMC FINANCE III S.A., a company existing under the laws of Luxembourg | ||
By:
/s/ Xxxxxxxx
Xxx Xxxx: Xxxxxxxx
Xxx
Title: Director |
||
FMC FINANCE VI S.A., a société anonyme (Public limited company) existing under the laws of Luxembourg | ||
By:
/s/ Xxxxxxxx
Xxx Xxxx: Xxxxxxxx
Xxx
Title: Director |
20
GUARANTORS:
|
FRESENIUS MEDICAL CARE DEUTSCHLAND GmbH, a German limited liability company | |
By:
/s/ Xx. Xxxxxx
Xxxxxxx Xxxx: Xx. Xxxxxx
Xxxxxxx
Title: Managing Director |
||
By:
/s/ Xxxxxxxx
Xxxxxx Xxxx: Xxxxxxxx
Xxxxxx
Title: Managing Director |
||
FRESENIUS MEDICAL CARE BETEILIGUNGSGESELLSCHAFT mbH, a German limited liability company | ||
By:
/s/ Xxxxxxx
Xxxxxxx Xxxx: Xxxxxxx
XxxxxxxTitle: Managing Director |
||
By:
/s/ Xx. Xxxxxx
Xxxxx Xxxx: Xx. Xxxxxx
XxxxxTitle: Managing Director |
||
FRESENIUS MEDICAL CARE US BETEILIGUNGSGESELLSCHAFT mbH, a German limited liability company | ||
By:
/s/ Xxxxx
Xxxxxx Xxxx: Xxxxx
XxxxxxTitle: Managing Director |
||
FRESENIUS MEDICAL CARE GmbH, a German limited liability company | ||
By:
/s/ Xxxxxxx
Xxxxx Xxxx: Xxxxxxx
XxxxxTitle: Managing Director |
||
By:
/s/ Xxxxxxx
Xxxxxx Xxxx: Xxxxxxx
Xxxxxx
Title: Managing Director |
21
GUARANTORS:
|
FRESENIUS MEDICAL CARE US ZWEI BETEILIGUNGSGESELLSCHAFT mbH, a German limited liability company | |
By:
/s/ Xxxxx
Xxxxxx Xxxx: Xxxxx
Xxxxxx
Title: Managing Director |
||
XXXXXXXXX MEDICAL CARE US DREI BETEILIGUNGSGESELLSCHAFT mbH, a German limited liability company | ||
By:
/s/ Xxxxx
Xxxxxx Xxxx: Xxxxx
Xxxxxx
Title: Managing Director |
||
FRESENIUS MEDICAL CARE US ZWEI VERMÖGENSVERWALTUNGS GmbH & Co. KG, a German limited partnership | ||
By: Fresenius Medical Care Vermögensverwaltungs GmbH,
a German limited liability company
|
||
Its General Partner | ||
By:
/s/ Xxxxx
Xxxxxx Xxxx: Xxxxx
Xxxxxx
Title: Managing Director |
||
FMC FINANCE II S.à x.x., a private limited company (société à responsabilité limitée) organized under the laws of Luxembourg | ||
By:
/s/ Xxxxxxxx
Xxx Xxxx: Xxxxxxxx
Xxx
Title: Manager |
22
ADMINISTRATIVE AGENT AND COLLATERAL AGENT | BANK OF AMERICA, N.A., for itself in its capacities as Administrative Agent and Collateral Agent on behalf of the lenders | |
By:
/s/ Xxxxxx
Xxx Xxxx: Xxxxxx
Xxx
Title: Vice President |
23
24
Incremental |
||||||||||||||||||||
Revolving |
||||||||||||||||||||
Revolving |
Commitments |
Revolving |
||||||||||||||||||
Commitments |
and Portion of |
Commitments |
||||||||||||||||||
Immediately |
Revolving |
After |
||||||||||||||||||
Prior to |
Revolving |
Commitments |
Establishment of |
Revolving |
||||||||||||||||
Amendment |
Commitment |
Subject of |
Incremental and |
Commitment |
||||||||||||||||
Lender Name | No. 3 | Percentage | Reallocation | Reallocation | Percentage | |||||||||||||||
AUSTRALIA & NEW ZEALAND BANKING GROUP LTD
|
$ | 21,500,000.00 | $ | 21,500,000.00 | 1.791666667 | % | ||||||||||||||
BANCO BILBAO VIZCAYA ARGENTARIA SA
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 5,982,456.14 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
BANCO ITAU EUROPA SA SECURSAL FINANCEIRA INTERNACIONAL
|
$ | 10,000,000.00 | 1.000000000 | % | $ | — | $ | 10,000,000.00 | 0.833333333 | % | ||||||||||
BANK OF AMERICA NA
|
$ | 79,970,407.98 | 7.997040798 | % | $ | (37,075,729.00 | ) | $ | 42,894,678.98 | 3.574556582 | % | |||||||||
BANK OF NEW YORK MELLON THE
|
$ | 17,684,210.52 | 1.768421052 | % | $ | 3,815,789.48 | $ | 21,500,000.00 | 1.000000000 | % | ||||||||||
BANK OF NOVA SCOTIA THE
|
$ | 29,824,561.40 | 2.000000000 | % | $ | 3,175,438.60 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
BANK OF TAIWAN NEW YORK AGENCY
|
$ | 3,508,771.93 | 0.350877193 | % | $ | 3,491,228.07 | $ | 7,000,000.00 | 0.583333333 | % | ||||||||||
BANK OF TOKYO MITSUBISHI UFJ TRUST COMPANY THE
|
$ | 10,526,315.79 | 1.052631579 | % | $ | 10,973,684.21 | $ | 21,500,000.00 | 1.791666667 | % | ||||||||||
BARCLAYS BANK PLC
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 5,982,456.14 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
BAYERISCHE LANDESBANK
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 1,982,456.14 | $ | 29,000,000.00 | 2.416666667 | % | ||||||||||
BHF BANK AKTIENGESELLSCHAFT
|
$ | 17,543,859.65 | 1.754385965 | % | $ | — | $ | 17,543,859.65 | 1.461988304 | % | ||||||||||
BNP PARIBAS
|
$ | 37,543,859.65 | 3.754385965 | % | $ | (4,543,859.65 | ) | $ | 33,000,000.00 | 2.750000000 | % | |||||||||
XXXXX XXX COMMERCIAL BANK LTD
|
$ | 1,666,666.67 | 0.166666667 | % | $ | 5,333,333.33 | $ | 7,000,000.00 | 0.583333333 | % | ||||||||||
CHINATRUST COMMERICAL BANK LTD
|
$ | 2,000,000.00 | 0.200000000 | % | $ | 69,113.92 | $ | 2,069,113.92 | 0.172426160 | % | ||||||||||
COMMERZBANK AG FILIALE LUXEMBOURG
|
$ | 51,842,105.26 | 5.184210526 | % | $ | (18,842,105.26 | ) | $ | 33,000,000.00 | 2.750000000 | % | |||||||||
CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 5,982,456.14 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
CREDIT INDUSTRIEL ET COMMERCIAL
|
$ | 6,929,824.56 | 0.692982456 | % | $ | 10,397,928.20 | $ | 17,327,752.76 | 1.443979397 | % | ||||||||||
CREDIT MUTUEL BANQUE DE L’ECONOMIE DU COMMERCE ET DE LA
MONETIQUE SA NIEDERLASSUNG DEUTSCHLAND
|
$ | 5,263,157.89 | 0.526315789 | % | $ | 6,409,089.35 | $ | 11,672,247.24 | 0.972687270 | % | ||||||||||
CREDIT SUISSE AG CAYMAN ISLANDS BRANCH
|
$ | 29,824,561.40 | 2.982456140 | % | $ | 3,175,438.60 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
DEUTSCHE APOTHEKER UND ARZTEBANK EG
|
$ | 10,526,315.79 | 1.052631579 | % | $ | — | $ | 10,526,315.79 | 0.877192983 | % | ||||||||||
DEUTSCHE BANK AG NEW YORK BRANCH
|
$ | 78,145,001.05 | 7.814500105 | % | $ | (35,250,322.07 | ) | $ | 42,894,678.98 | 3.574556582 | % | |||||||||
DNB NOR BANK ASA
|
$ | 29,000,000.00 | $ | 29,000,000.00 | 2.416666667 | % | ||||||||||||||
DZ BANK AG (DEUTSCHE ZENTRAL-GENOSSENSCHAFTSBANK)
|
$ | 39,350,877.19 | 3.935087719 | % | $ | (6,350,877.19 | ) | $ | 33,000,000.00 | 2.750000000 | % | |||||||||
HSBC BANK PLC
|
$ | 17,543,859.65 | 1.754385965 | % | $ | 3,956,140.35 | $ | 21,500,000.00 | 1.791666667 | % | ||||||||||
HUNTINGTON NATIONAL BANK
|
$ | 12,000,000.00 | $ | 12,000,000.00 | 1.000000000 | % | ||||||||||||||
INTESA SANPAOLO SPA
|
$ | 17,543,859.65 | 1.754385965 | % | $ | 5,956,140.35 | $ | 23,500,000.00 | 1.958333333 | % | ||||||||||
JPMORGAN CHASE BANK NATIONAL ASSOCIATION
|
$ | 29,824,561.40 | 2.982456140 | % | $ | 13,175,438.60 | $ | 43,000,000.00 | 3.583333333 | % | ||||||||||
KEYBANK NATIONAL ASSOCIATION
|
$ | 5,263,157.89 | 0.526315789 | % | $ | 418,721.11 | $ | 5,681,879.00 | 0.473489917 | % | ||||||||||
KFW IPEX BANK GMBH
|
$ | 24,576,199.54 | 2.457619954 | % | $ | 8,423,800.46 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
LANDESBANK BADEN WUERTTEMBERG NEW YORK AND/OR CAYMAN ISLANDS
BRANCH
|
$ | 32,631,578.95 | 3.263157895 | % | $ | 368,421.05 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
LANDESBANK BADEN WURTTEMBERG
|
$ | 19,561,403.51 | 1.956140351 | % | $ | (19,561,403.51 | ) | $ | — | 0.000000000 | % | |||||||||
LANDESBANK HESSEN THUERINGEN GIROZENTRALE
|
$ | 19,350,877.19 | 1.935087719 | % | $ | 9,649,122.81 | $ | 29,000,000.00 | 2.416666667 | % | ||||||||||
MEDIOBANCA INTERNATIONAL (LUXEMBOURG) SA
|
$ | 1,666,666.67 | 0.166666667 | % | $ | 31,333,333.33 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
MIZUHO CORPORATE BANK NEDERLAND NV
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 5,982,456.14 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
NORDEA BANK FINLAND PLC NEW YORK AND GRAND CAYMAN BRANCHES
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 1,982,456.14 | $ | 29,000,000.00 | 2.416666667 | % | ||||||||||
PNC BANK NA
|
$ | 5,526,315.79 | 0.552631579 | % | $ | 6,473,684.21 | $ | 12,000,000.00 | 1.000000000 | % | ||||||||||
RAIFFEISEN ZENTRALBANK OSTERREICH AG
|
$ | 14,035,087.72 | 1.403508772 | % | $ | — | $ | 14,035,087.72 | 1.000000000 | % | ||||||||||
ROYAL BANK OF CANADA
|
$ | 17,000,000.00 | $ | 17,000,000.00 | 1.416666667 | % | ||||||||||||||
ROYAL BANK OF SCOTLAND PLC, THE NIEDERLASSUNG FRANKFURT
|
$ | 59,701,754.39 | 5.970175439 | % | $ | (26,701,754.39 | ) | $ | 33,000,000.00 | 2.750000000 | % | |||||||||
RZB FINANCE LLC
|
$ | 3,508,771.93 | 0.350877193 | % | $ | 91,228.07 | $ | 3,600,000.00 | 0.300000000 | % | ||||||||||
SOCIETE GENERALE
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 5,982,456.14 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
SOVEREIGN BANK
|
$ | 33,000,000.00 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||||||
STATE BANK OF INDIA
|
$ | 5,263,157.89 | 0.526315789 | % | $ | 1,736,842.11 | $ | 7,000,000.00 | 0.583333333 | % | ||||||||||
SUMITOMO MITSUI BANKING CORPORATION
|
$ | 16,150,496.72 | 1.615049672 | % | $ | 16,849,503.28 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
SUNTRUST BANK
|
$ | 23,771,929.82 | 2.377192982 | % | $ | 9,228,070.18 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
TAIPEI FUBON COMMERCIAL BANK LA BRANCH
|
$ | 1,754,385.96 | 0.175438596 | % | $ | — | $ | 1,754,385.96 | 0.146198830 | % | ||||||||||
TD BANK
|
$ | 29,000,000.00 | $ | 29,000,000.00 | 2.416666667 | % | ||||||||||||||
UNICREDIT BANK AG
|
$ | 16,275,628.83 | 1.627562883 | % | $ | (4,275,628.83 | ) | $ | 12,000,000.00 | 1.000000000 | % | |||||||||
UNICREDIT BANK AUSTRIA AG (FORMERLY BANK AUSTRIA CREDITANSTALT
AG)
|
$ | 10,741,915.03 | 1.074191503 | % | $ | 3,258,084.97 | $ | 14,000,000.00 | 1.166666667 | % | ||||||||||
US BANK
|
$ | 17,000,000.00 | $ | 17,000,000.00 | 1.416666667 | % | ||||||||||||||
XXXXX FARGO BANK NA
|
$ | 27,017,543.86 | 2.701754386 | % | $ | 5,982,456.14 | $ | 33,000,000.00 | 2.750000000 | % | ||||||||||
WESTLB AG NEW YORK BRANCH
|
$ | 27,017,543.86 | 2.701754386 | % | $ | (3,517,543.86 | ) | $ | 23,500,000.00 | 1.958333333 | % | |||||||||
TOTAL
|
$ | 1,000,000,000.00 | 100.00 | % | $ | 200,000,000.00 | $ | 1,200,000,000.00 | 100.000000000 | % |
25
Incremental |
||||||||||||||||||||
Tranche A Term |
||||||||||||||||||||
Loans and Portion |
Tranche A Term |
|||||||||||||||||||
Tranche A Term |
of Existing |
Loans After |
||||||||||||||||||
Loans Immediately |
Tranche A |
Tranche A Term |
Establishment of |
Tranche A |
||||||||||||||||
Prior to |
Term Loan |
Loan Subject of |
Incremental and |
Term Loan |
||||||||||||||||
Lender Name | Amendment No. 3 | Percentage | Reallocation | Reallocation | Percentage | |||||||||||||||
AUSTRALIA & NEW ZEALAND BANKING GROUP LTD
|
$ | 23,500,000.00 | $ | 23,500,000.00 | 1.721611722 | % | ||||||||||||||
BANCO BILBAO VIZCAYA ARGENTARIA SA
|
$ | 35,516,100.38 | 2.701754386 | % | $ | 3,483,899.62 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
BANK OF AMERICA NA
|
$ | 101,411,941.08 | 7.714533794 | % | $ | (58,798,136.11 | ) | $ | 42,613,804.97 | 3.121890474 | % | |||||||||
BANK OF NEW YORK MELLON THE
|
$ | 19,960,509.70 | 1.518421056 | % | $ | 3,539,490.30 | $ | 23,500,000.00 | 1.000000000 | % | ||||||||||
BANK OF NOVA SCOTIA THE
|
$ | 10,601,551.41 | 0.000000000 | % | $ | (401,551.41 | ) | $ | 10,200,000.00 | 0.747252747 | % | |||||||||
BANK OF TAIWAN NEW YORK AGENCY
|
$ | 4,612,480.56 | 0.350877192 | % | $ | 3,387,519.44 | $ | 8,000,000.00 | 0.586080586 | % | ||||||||||
BANK OF TOKYO MITSUBISHI UFJ TRUST COMPANY THE
|
$ | 13,837,441.73 | 1.052631581 | % | $ | 9,662,558.27 | $ | 23,500,000.00 | 1.721611722 | % | ||||||||||
BARCLAYS BANK PLC
|
$ | 35,516,100.38 | 2.701754386 | % | $ | 3,483,899.62 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
BAYERISCHE LANDESBANK
|
$ | 35,516,100.38 | 2.701754386 | % | $ | (2,516,100.38 | ) | $ | 33,000,000.00 | 2.417582418 | % | |||||||||
BHF BANK AKTIENGESELLSCHAFT
|
$ | 23,062,402.85 | 1.754385966 | % | $ | — | $ | 23,062,402.85 | 1.689553322 | % | ||||||||||
BNP PARIBAS
|
$ | 49,353,542.11 | 3.754385967 | % | $ | (10,353,542.11 | ) | $ | 39,000,000.00 | 2.857142857 | % | |||||||||
XXXXX XXX COMMERCIAL BANK LTD
|
$ | 2,190,928.27 | 0.166666667 | % | $ | 5,809,071.73 | $ | 8,000,000.00 | 0.586080586 | % | ||||||||||
CHINATRUST COMMERICAL BANK LTD
|
$ | 2,629,113.92 | 0.200000000 | % | $ | (69,113.92 | ) | $ | 2,560,000.00 | 0.187545788 | % | |||||||||
COMMERZBANK AG FILIALE LUXEMBOURG
|
$ | 85,600,624.50 | 6.511747073 | % | $ | (46,600,624.50 | ) | $ | 39,000,000.00 | 2.857142857 | % | |||||||||
CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK
|
$ | 35,516,100.38 | 2.701754386 | % | $ | 3,483,899.62 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
CREDIT INDUSTRIEL ET COMMERCIAL
|
$ | 9,287,291.93 | 0.706495968 | % | $ | 10,384,897.90 | $ | 19,672,189.83 | 1.441186068 | % | ||||||||||
CREDIT MUTUEL BANQUE DE L’ECONOMIE DU COMMERCE ET DE LA
MONETIQUE SA NIEDERLASSUNG DEUTSCHLAND
|
$ | 6,918,720.82 | 0.526315787 | % | $ | 6,409,089.35 | $ | 13,327,810.17 | 0.976396349 | % | ||||||||||
CREDIT SUISSE AG CAYMAN ISLANDS BRANCH
|
$ | 39,206,084.82 | 2.982456139 | % | $ | (206,084.82 | ) | $ | 39,000,000.00 | 2.857142857 | % | |||||||||
DEUTSCHE APOTHEKER UND ARZTEBANK EG
|
$ | 13,837,441.73 | 1.052631581 | % | $ | — | $ | 13,837,441.73 | 1.013731995 | % | ||||||||||
DEUTSCHE BANK AG NEW YORK BRANCH
|
$ | 102,636,034.95 | 7.807652153 | % | $ | (60,022,229.99 | ) | $ | 42,613,804.96 | 3.121890473 | % | |||||||||
DNB NOR BANK ASA
|
$ | 33,000,000.00 | $ | 33,000,000.00 | 2.417582418 | % | ||||||||||||||
DZ BANK AG (DEUTSCHE ZENTRAL-GENOSSENSCHAFTSBANK)
|
$ | 53,043,526.54 | 4.035087720 | % | $ | (14,043,526.54 | ) | $ | 39,000,000.00 | 2.857142857 | % | |||||||||
E SUN COMMERCIAL BANK LTD
|
$ | 7,105,713.32 | 0.540540541 | % | $ | — | $ | 7,105,713.32 | 0.520565078 | % | ||||||||||
HSBC BANK PLC
|
$ | 23,062,402.85 | 1.754385966 | % | $ | 437,597.15 | $ | 23,500,000.00 | 1.721611722 | % | ||||||||||
HUNTINGTON NATIONAL BANK
|
$ | 13,000,000.00 | $ | 13,000,000.00 | 0.952380952 | % | ||||||||||||||
INTESA SANPAOLO SPA
|
$ | 23,062,402.85 | 1.754385966 | % | $ | 3,437,597.15 | $ | 26,500,000.00 | 1.941391941 | % | ||||||||||
JPMORGAN CHASE BANK NATIONAL ASSOCIATION
|
$ | 39,206,084.82 | 2.982456139 | % | $ | (10,206,084.82 | ) | $ | 29,000,000.00 | 2.124542125 | % | |||||||||
KEYBANK NATIONAL ASSOCIATION
|
$ | 6,918,720.82 | 0.526315787 | % | $ | (418,720.82 | ) | $ | 6,500,000.00 | 0.476190476 | % | |||||||||
KFW IPEX BANK GMBH
|
$ | 40,787,826.89 | 3.102781246 | % | $ | (1,787,826.89 | ) | $ | 39,000,000.00 | 2.857142857 | % | |||||||||
LANDESBANK BADEN WUERTTEMBERG NEW YORK AND/OR CAYMAN ISLANDS
BRANCH
|
$ | 42,896,069.31 | 3.263157897 | % | $ | (3,896,069.31 | ) | $ | 39,000,000.00 | 2.857142857 | % | |||||||||
LANDESBANK BADEN WURTTEMBERG
|
$ | 25,181,650.69 | 1.915599812 | % | $ | (25,181,650.69 | ) | $ | — | 0.000000000 | % | |||||||||
LANDESBANK HESSEN THUERINGEN GIROZENTRALE
|
$ | 25,011,487.53 | 1.902655286 | % | $ | 7,988,512.47 | $ | 33,000,000.00 | 2.417582418 | % | ||||||||||
MEDIOBANCA INTERNATIONAL (LUXEMBOURG) SA
|
$ | 3,734,536.85 | 0.284090911 | % | $ | 35,265,463.15 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
MEGA INTERNATIONAL COMMERCIAL BANK CO LTD
|
$ | 3,286,392.40 | 0.250000000 | % | $ | — | $ | 3,286,392.40 | 0.240761348 | % | ||||||||||
MIZUHO CORPORATE BANK NEDERLAND NV
|
$ | 35,516,100.38 | 2.701754386 | % | $ | 3,483,899.62 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
NORDEA BANK FINLAND PLC NIEDERLASSUNG DEUTSCHLAND
|
$ | 35,516,100.38 | 2.701754386 | % | $ | (2,516,100.38 | ) | $ | 33,000,000.00 | 2.417582418 | % | |||||||||
PB CAPITAL CORPORATION
|
$ | 3,552,856.65 | 0.270270270 | % | $ | 0.35 | $ | 3,552,857.00 | 0.260282564 | % | ||||||||||
PNC BANK NA
|
$ | 17,509,388.63 | 1.331961196 | % | $ | (4,509,388.63 | ) | $ | 13,000,000.00 | 0.952380952 | % | |||||||||
RAIFFEISEN ZENTRALBANK OSTERREICH AG
|
$ | 18,449,922.28 | 1.403508772 | % | $ | — | $ | 18,449,922.28 | 1.000000000 | % | ||||||||||
ROYAL BANK OF CANADA
|
$ | 18,000,000.00 | $ | 18,000,000.00 | 1.318681319 | % | ||||||||||||||
ROYAL BANK OF SCOTLAND PLC, THE NIEDERLASSUNG FRANKFURT
|
$ | 78,481,356.89 | 5.970175440 | % | $ | (39,481,356.89 | ) | $ | 39,000,000.00 | 2.857142857 | % | |||||||||
RZB FINANCE LLC
|
$ | 4,612,480.56 | 0.350877192 | % | $ | (112,480.56 | ) | $ | 4,500,000.00 | 0.329670330 | % | |||||||||
SCOTIABANC INC
|
$ | 24,869,996.56 | 1.891891890 | % | $ | 3,930,003.44 | $ | 28,800,000.00 | 2.109890110 | % | ||||||||||
SOCIETE GENERALE
|
$ | 35,516,100.38 | 2.701754386 | % | $ | 3,483,899.62 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
SOVEREIGN BANK
|
$ | 39,000,000.00 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||||||
STATE BANK OF INDIA
|
$ | 6,918,720.82 | 0.526315787 | % | $ | 1,081,279.18 | $ | 8,000,000.00 | 0.586080586 | % | ||||||||||
SUMITOMO MITSUI BANKING CORPORATION
|
$ | 21,053,105.11 | 1.601536162 | % | $ | 17,946,894.89 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
SUNTRUST BANK
|
$ | 22,343,591.84 | 1.699705109 | % | $ | 16,656,408.16 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
TAIPEI FUBON COMMERCIAL BANK LA BRANCH
|
$ | 5,917,660.49 | 0.450163870 | % | $ | — | $ | 5,917,660.49 | 0.433528241 | % | ||||||||||
TD BANK
|
$ | 33,000,000.00 | $ | 33,000,000.00 | 2.417582418 | % | ||||||||||||||
UNICREDIT BANK AG
|
$ | 21,395,241.18 | 1.627562882 | % | $ | (8,395,241.18 | ) | $ | 13,000,000.00 | 0.952380952 | % | |||||||||
UNICREDIT BANK AUSTRIA AG (FORMERLY BANK AUSTRIA CREDITANSTALT
AG)
|
$ | 14,120,859.19 | 1.074191503 | % | $ | 1,879,140.81 | $ | 16,000,000.00 | 1.172161172 | % | ||||||||||
US BANK
|
$ | 18,000,000.00 | $ | 18,000,000.00 | 1.318681319 | % | ||||||||||||||
XXXXX FARGO BANK NA
|
$ | 12,760,053.51 | 0.970673305 | % | $ | 26,239,946.49 | $ | 39,000,000.00 | 2.857142857 | % | ||||||||||
WESTLB AG NEW YORK BRANCH
|
$ | 35,516,100.38 | 2.701754386 | % | $ | (9,016,100.38 | ) | $ | 26,500,000.00 | 1.941391941 | % | |||||||||
TOTAL
|
$ | 1,314,556,962.00 | 100.00 | % | $ | 50,443,038.00 | $ | 1,365,000,000.00 | 100.00 | % |
26
Short-Term Borrowings (funded)
|
101.4 | see Attachment A (incl. unfunded commitments) | ||||
Capital Lease Obligations (current & non-current)
|
15.5 | see Attachment B | ||||
Long-Term Debt incl. current portion (funded)
|
597.7 | see Attachment A (incl. unfunded commitments) | ||||
Purchase Money Obligations
|
38.7 | see Attachment C | ||||
Synthetic Lease Obligations
|
6.2 | see Attachment D | ||||
Guarantee Obligations
|
0.4 | see Attachment D |
27
current |
non current |
|||||||||||||||||||||||
portion of |
portion of |
|||||||||||||||||||||||
Short term |
long-term |
long-term |
Unfunded |
|||||||||||||||||||||
$ in millions | borrowings | debt | debt | Total | Commitments | Lender/Details | Maturity | |||||||||||||||||
FMC AG & Co. KGaA
|
245.4 | 245.4 | — | Schuldscheindarlehen (“Euro Notes”) | 2012/2014 | |||||||||||||||||||
FMC AG & Co. KGaA
|
336.4 | 336.4 | — | European Investment Bank | 2013/2014 | |||||||||||||||||||
FMC AG & Co. KGaA
|
— | 26.5 | various umbrella facilities to be allocated to subsidiaries in Asia-Pacific, Latin America and Europe |
until revoked/ yearly review |
||||||||||||||||||||
FMC Italia S.p.A
|
15.4 | 15.4 | 1.2 | Banca Monte Paschi di Siena BNL Intesa SanPaolo |
until revoked until revoked until revoked |
|||||||||||||||||||
FMC Espana S.A
|
6.1 | 6.1 | 6.1 |
BBVA Caja Madrid Commerzbank |
Feb 2011 Aug 2010 |
|||||||||||||||||||
Nov 2010 | ||||||||||||||||||||||||
FDH Turkey
|
10.3 | 10.3 | 19.9 |
Ak Bank IS Bank HSBC Halk Bank Garanti Bank VakifBank Yapi Kredi Bank |
Dec 2010 Dec 2010 Dec 2010 Dec 2010 Dec 2010 Dec 2010 Dec 2010 |
|||||||||||||||||||
FMC Holdings Inc.
|
11.4 | 11.4 | — | CP issued to unconsolidated joint ventures insurance financing |
until revoked Jul 2011 |
|||||||||||||||||||
FMC Colombia S.A.
|
5.0 | 0.5 | 5.5 | 36.8 |
Banco Colpatria Bancocolumbia Royal Bank of Scotland |
May 2011 Aug 2011 until revoked |
||||||||||||||||||
NephroCare Chile
|
4.1 | 4.1 | 0.5 | Banco de Credito e Inversiones Royal Bank of Scotland |
until revoked until revoked |
|||||||||||||||||||
Pentafarma S.A.
|
4.2 | 4.2 | 0.8 | Banco de Credito e Inversiones Royal Bank of Scotland |
until revoked until revoked |
|||||||||||||||||||
FMC de Mexico
|
4.7 | 4.7 | 0.3 | Scotiabank | Aug 2010 | |||||||||||||||||||
FMC Japan K.K.
|
25.7 | 2.8 | 9.3 | 37.8 | 16.1 |
Deutsche Bank Development Bank of Japan DZ Bank Furusato Royal Bank of Scotland Saitamaken |
until revoked Jan 2015 yearly review Nov 2014 until revoked Jul/Dec 2013 |
|||||||||||||||||
FMC Philippines
|
2.2 | 2.2 | 1.3 | Deutsche Bank | yearly review | |||||||||||||||||||
FMC Australia
|
6.1 | 6.1 | 1.9 |
Deutsche Bank Royal Bank of Scotland |
yearly review until revoked |
|||||||||||||||||||
FMC Groupe France
|
0.6 | 0.6 | 3.7 |
BNP Paribas Credit du Nord |
until revoked Jul 2014 |
|||||||||||||||||||
Xxxxxxxxx Xxxxxxxx Co
|
1.6 | 1.6 | — |
Development Bank of Japan Furusato Mizuho SMBC |
May 2011 Dec 2010 Jun 2011 Jun 2011 |
|||||||||||||||||||
other subsidiaries (debt less than 2 Mio USD per entity)
|
6.3 | 0.4 | 0.7 | 7.4 | 106.7 | various banks providing commitments on local level and banks providing umbrella facilities |
until revoked/ regular review |
|||||||||||||||||
Total
|
101.4 | 4.8 | 592.9 | 699.1 | 221.8 |
28
Current |
Non current |
Total Capital |
||||||||||
$ in millions | portion | portion | Leases | |||||||||
Provider France
|
0.4 | 3.2 | 3.6 | |||||||||
NMC Portugal
|
0.2 | 1.3 | 1.4 | |||||||||
FMC Srbija D.o.o.
|
0.3 | 0.2 | 0.5 | |||||||||
FMC Holdings Inc.
|
0.2 | 2.2 | 2.4 | |||||||||
FMC Colombia S.A.
|
0.7 | 2.2 | 2.9 | |||||||||
NephroCare Chile
|
0.2 | 0.2 | 0.3 | |||||||||
FMC Japan K.K.
|
1.8 | 2.1 | 3.9 | |||||||||
Other subsidiaries
|
0.2 | 0.3 | 0.4 | |||||||||
Total
|
3.9 | 11.5 | 15.5 |
29
short-term purchase money obligations | ||||||||||||||||
current portion |
non current portion |
|||||||||||||||
short term payments |
payments for |
payment for |
Total as of |
|||||||||||||
$ in millions | for acquisitions | acquisitions | acqusitions | 06/30/10 | ||||||||||||
FMC NA RSI
|
2.1 | 5.0 | 7.1 | |||||||||||||
FMC Italia S.p.A
|
0.5 | 1.2 | 1.7 | |||||||||||||
NMC of Spain
|
2.1 | 1.1 | 3.3 | |||||||||||||
FMC Estonia OÜ
|
0.3 | 0.3 | ||||||||||||||
FMC Saudi Arabia Ltd.
|
3.7 | 3.7 | 7.5 | |||||||||||||
FMC Beteiligungsgesellschaft
|
0.5 | 0.5 | ||||||||||||||
FMC Srbija D.o.o. PC
|
0.4 | 0.4 | ||||||||||||||
Nephrocare Polska
|
0.8 | 0.8 | ||||||||||||||
FMC Japan K.K.
|
1.6 | 1.6 | ||||||||||||||
FMC Holdings Inc.
|
6.6 | 8.3 | 14.9 | |||||||||||||
Other subsidiaries
|
0.4 | 0.3 | 0.7 | |||||||||||||
Total
|
8.7 | 12.0 | 18.0 | 38.7 |
30
Synthetic Lease |
Total as of |
|||||||||||
$ in millions | Guarantees | Obligations | 06/30/10 | |||||||||
FMC AG & Co. KGaA
|
0.4 | 0.4 | ||||||||||
Renal Service Ltd.
|
6.2 | 6.2 | ||||||||||
Total
|
0.4 | 6.2 | 6.6 |
31
Facility Amount in |
||||||||
Subsidiary | Type | Beneficiary | Details | Transaction Currency | ||||
Asia Renal Care (SEA)
PTE LTD |
Share Charge |
DBS Bank LTD., Singapore |
Share charge by ARC Cayman in favour of DBS Bank LTD. in respect of 100% of the issued and paid up share in the capital of Asia Renal Care (SEA) PTE LTD | USD 12.000 | ||||
Debenture
|
Deed of Debenture executed by Asia Renal Care (SEA) PTE LTD in favour of DBS Bank LTD. in respect of all its property and assets | |||||||
Account Pledge
|
Account pledge by Asia Renal Care (SEA) PTE LTD in favour of DBS Bank LTD. over its monies in bank account maintained with the lender in Taiwan | |||||||
Asia Renal Care (SEA)
PTE LTD, Taiwan Branch |
Share Charge |
DBS Bank LTD., Taipei Branch |
Share charge by ARC Cayman in favour of DBS Bank LTD. in respect of 100% of the issued and paid up share in the capital of Asia Renal Care (SEA) PTE LTD, Taiwan Branch | TWD equivalent of USD 8.000 | ||||
Debenture
|
Deed of Debenture executed by Asia Renal Care (SEA) PTE LTD in favour of DBS Bank LTD., Taipei Branch in respect of all its property and assets | |||||||
Account Pledge
|
Account pledge by Asia Renal Care (SEA) PTE LTD, Taipei Branch in favour of DBS Bank LTD., Taipei Branch over its monies in bank account maintained with the lender in Taiwan | |||||||
FMC Romania
|
Pledge on accounts receivable | ABN AMRO Bank Romania SA. | Pledge on accounts receivable under existing short-term credit facility |
EUR 500 |
||||
Nephrocare Romania
|
Pledge on accounts receivable | ABN AMRO Bank Romania SA. | Pledge on accounts receivable under existing short-term credit facility |
EUR 1.600 |
||||
FMC Finland
|
Deposit arrangement |
Nordea Bank Finland |
Liens deposit for office rent in favour of Nordea Bank Finland | EUR 37 | ||||
FMC Japan
|
Mortgage | Development Bank of Japan | Fixed charge over real estate Buzen plant |
JPY 741.000 |
||||
Xxxxxxxxx Xxxxxxxx
|
Mortgage |
Development Bank of Japan Development Bank of Japan SMBC Mizuho Bank |
Fixed charge over real estate Inkai plant/ spinning line 1 Fixed charge over real estate Inkai plant/ spinning line 2 Fixed charge over real estate Inkai plant/ spinning line 2 Fixed charge over real estate Inkai plant/ spinning line 2 |
JPY 141.050 |
32
Amount of capital |
||||||||||||||||
% of FMC’s |
stock/other securities |
Amount of |
Total investment |
|||||||||||||
directl/indirect |
(= book value of investment) |
loans/advances |
in USD million |
|||||||||||||
Name of investment | ownership | in USD million | in USD million | 06/30/2010 | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | ||||||||||||
[*]
|
[*] | % | [*] | [*] | [*] | |||||||||||
Sum of total investments
|
[*] |
33
Amount in USD |
||||||
Lender (= credit party) | Borrower | as of 06/30/10 | ||||
FMC AG & Co. KGaA
|
FMC South East Asia (Australia) | 42,617,221 | ||||
FMC AG & Co. KGaA
|
FMC Singapore | 715,649 | ||||
FMC AG & Co. KGaA
|
NMC Dialysebehandlung GmbH, Germany | 4,732,922 | ||||
FMC AG & Co. KGaA
|
Xxxxxxxx GmbH, Germany | 15,701,604 | ||||
FMC AG & Co. KGaA
|
FMC de Mexico | 33,184,256 | ||||
FMC AG & Co. KGaA
|
FMC Japan K.K. | 141,628,442 | ||||
FMC AG & Co. KGaA
|
NMC Centro Medico Nacional Ltda., Portugal | 19,650,262 | ||||
FMC AG & Co. KGaA
|
FMC Argentinia | 13,625,620 | ||||
FMC AG & Co. KGaA
|
FMC Espana | 5,521,950 | ||||
FMC AG & Co. KGaA
|
FMC Nephrologica S.A. Lugano | 108,982 | ||||
FMC AG & Co. KGaA
|
Osaühing FMC Estonia | 1,275,100 | ||||
FMC AG & Co. KGaA
|
Renal Services Ltd., UK | 12,440,343 | ||||
FMC AG & Co. KGaA
|
Kawasumi, Japan | 3,842,969 | ||||
FMC AG & Co. KGaA
|
FMC Lebanon | 1,687,515 | ||||
FMC AG & Co. KGaA
|
FMC S.P. Moskau, Russia | 3,681,300 | ||||
FMC AG & Co. KGaA
|
FMC Polska S.A., Polen | 3,677,533 | ||||
FMC AG & Co. KGaA
|
Nephrocare, Chile | 880,107 | ||||
FMC AG & Co. KGaA
|
FMC Taiwan | 4,626,725 | ||||
FMC AG & Co. KGaA
|
Nephrocare Taiwan | 17,569,803 | ||||
FMC AG & Co. KGaA
|
FMC Korea | 4,901,864 | ||||
FMC AG & Co. KGaA
|
Yeolin Medical Foundation Korea | 6,343,989 | ||||
FMC AG & Co. KGaA
|
Nephrocare Service Japan K.K. | 1,798,680 | ||||
FMC AG & Co. KGaA
|
Nephrocare Hongkong | 1,615,536 | ||||
FMC AG & Co. KGaA
|
FMC Hongkong | 13,709,156 | ||||
FMC AG & Co. KGaA
|
Biocare Technology Co. Hongkong | 15,504,829 | ||||
FMC AG & Co. KGaA
|
FMC Ireland | 2,675,078 | ||||
FMC AG & Co. KGaA
|
FMC Malaysia | 1,960,850 | ||||
FMC AG & Co. KGaA
|
FMC Nephrologica D- GmbH | 26,407,467 | ||||
FMC AG & Co. KGaA
|
NephroCare Thailand Ltd. | 2,418,434 | ||||
FMC AG & Co. KGaA
|
FMC (Jiangsu) Co. Ltd. - USD | 6,046,156 | ||||
FMC AG & Co. KGaA
|
FMC Peru | 86,010 | ||||
FMC AG & Co. KGaA
|
FMC Ukraine TOV | 612,323 | ||||
FMC AG & Co. KGaA
|
FMC Saudi Arabia Ltd. (SAR) | 7,512,497 | ||||
418,761,170 | ||||||
FMC Beteiligungsgesellschaft
|
Fresenius Nephrocare Polska | 21,704,699 | ||||
FMC Beteiligungsgesellschaft
|
Fresenius Diyaliz Hitzmetler A.S. Turkey | 3,421,283 | ||||
FMC Beteiligungsgesellschaft
|
FMC Holding ooo Moskau Russia | 1,840,650 | ||||
FMC Beteiligungsgesellschaft
|
Fresenius Nephrocare Romania s.r.l. | 14,082,608 | ||||
FMC Beteiligungsgesellschaft
|
FMC Lebanon | 159,465 |
34
Amount in USD |
||||||
Lender (= credit party) | Borrower | as of 06/30/10 | ||||
FMC Beteiligungsgesellschaft
|
FMC Brasil Ltda. | 27,010,161 | ||||
FMC Beteiligungsgesellschaft
|
FMC South Africa | 7,226,444 | ||||
FMC Beteiligungsgesellschaft
|
Nephrocare D-GmbH | 21,676,722 | ||||
FMC Beteiligungsgesellschaft
|
FMC Dijalizna Njega d.o.o. Banja Luka | 3,804,010 | ||||
FMC Beteiligungsgesellschaft
|
Holiday Dialysis Intern. Holdings B.V. | 552,195 | ||||
FMC Beteiligungsgesellschaft
|
FMC Adsorber Tec GmbH | 613,550 | ||||
FMC Beteiligungsgesellschaft
|
Fresenius Nephrocare Russia | 1,614,605 | ||||
103,706,391 | ||||||
FMC Finance II S.à.x.x.
|
FMC SMAD S.A., France | 16,566,900 | ||||
FMC Finance II S.à.x.x.
|
FMC Ireland Ltd. | 5,618,340 | ||||
FMC Finance II S.à.x.x.
|
Nephrocare Polska | 463,440 | ||||
FMC Finance II S.à.x.x.
|
Renal Service Ltd., UK | 28,592,222 | ||||
FMC Finance II S.à.x.x.
|
FMC Groupe France | 18,727,800 | ||||
FMC Finance II S.à.x.x.
|
Xxxxxxxx GmbH, Germany | 11,859,798 | ||||
81,828,500 | ||||||
FMCD
|
FMC Adsorber Tec GmbH | 415,171 | ||||
415,171 | ||||||
Total Loans
|
604,711,232 |
35
Amount in USD |
||||
Subsidiary | as of 06/30/10 | |||
FMC GmbH
|
448,328.11 | |||
FMC Portugal S.A.
|
179,185.52 | |||
NMC Portugal
|
225,753.80 | |||
FM Hizmetler PC TRY
|
228,183.04 | |||
Nephrocare Polska
|
284,854.68 | |||
FMC Brazil (PC)
|
194,893.76 | |||
FMC Japan (J/PV)
|
1,965,451.02 | |||
Saudi Advance Renal
|
162,120.30 | |||
FMC Malaysia SAP/PC
|
290,020.62 | |||
Clinix Renal Care PC
|
130,913.61 | |||
Other Subsidiaries (< 100.000 USD)
|
33,417.74 | |||
4,143,122.20 | ||||
36
Amount in USD |
||||
Subsidiary | as of 06/30/10 | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
[*]
|
[*] | |||
Other Subsidiaries (< [*] USD)
|
[*] | |||
[*] | ||||
37
Amount in USD |
||||
Subsidiary | as of 06/30/10 | |||
FMC NA Corporate
|
8,710,000.00 | |||
8,710,000.00 | ||||
38
Restricted Payments | ||||
2011
|
$ | 330 million | ||
2012
|
$ | 360 million | ||
2013
|
$ | 390 million |
39
To: | Bank of America, N.A., as Administrative Agent under each of the Bank Credit Agreement and the Term Loan Credit Agreement (each as defined below) |
Re: | Bank Credit Agreement, dated as of March 31, 2006 (as further amended, restated, extended, supplemented or otherwise modified, the “Bank Credit Agreement”) among FRESENIUS MEDICAL CARE AG & Co. KGaA, a German partnership limited by shares, XXXXXXXXX MEDICAL CARE HOLDINGS, INC., a New York corporation, and the other Borrowers identified therein, the Guarantors identified therein, the Lenders party thereto, and BANK OF AMERICA, N.A., as Administrative Agent. Capitalized terms used herein and not otherwise defined have the meanings provided in the Bank Credit Agreement. |
40
41
42
to Compliance Certificate
FINANCIAL STATEMENTS
See attached.
43
to Compliance Certificate
COVENANT COMPLIANCE ANALYSES AND INFORMATION
I. Section 8.11(a) — Consolidated Leverage Ratio: | ||||||
A.
|
Consolidated Funded Debt | |||||
1. All obligations for borrowed money, whether current or long-term (including the Obligations), and all obligations evidenced by bonds, debentures, notes, loan agreements or other similar instruments (excluding Indebtedness in respect of convertible bonds referred to in Section 8.03(g)) | $ | |||||
2. All purchase money indebtedness (including indebtedness and obligations in respect of conditional sales and title retention arrangements, except for customary conditional sales and title retention arrangements with suppliers that are entered into in the ordinary course of business) and all indebtedness and obligations in respect of the deferred purchase price of property or services (other than trade accounts payable incurred the ordinary course of business and payable on customary trade terms) | $ | |||||
3. All obligations under financial letters of credit issued to support tax obligations of FMCH and its subsidiaries for the payment of such obligations in connection with the settlement of claims related to the X.X. Xxxxx bankruptcy | $ | |||||
4. Attributable Principal Amount of capital leases and Synthetic Leases | $ | |||||
5. Attributable Principal Amount of Securitization Transactions | $ | |||||
6. All preferred stock and comparable equity interests providing for mandatory redemption, sinking fund or other like payments issued to a Person that is not a member of the Consolidated Group | $ | |||||
7. Support Obligations in respect of Funded Debt of another Person | $ | |||||
8. Funded Debt of any partnership or joint venture or other similar entity in which such Person is a general partner or joint venturer, and, as such, has personal liability for such obligations, but only to the extent there is recourse to such Person for payment thereof | $ | |||||
9. Consolidated Funded Debt (sum of IA1 + IA2 + IA3 + IA4 + IA5 + IA6 + IA7 + IA8) | $ | |||||
B.
|
Pro Forma Effect | |||||
1. Acquisitions | $ | |||||
2. Dispositions | $ | |||||
3. Pro Forma Effect (IB1 + IB2); provided, where the aggregate consideration paid or payable by any member of the Consolidated Group in connection with such Disposition or Acquisition is reasonably expected (taking the amount of cash and Cash Equivalents and the fair market value of any non-cash consideration paid or payable and the amount of debt assumed, as reasonably determined by FMCAG) to be $50 million or less, FMCAG may elect whether or not to make the adjustments otherwise required. | $ | |||||
C.
|
Up to $250 million in cash and Cash Equivalents held by the members of the Consolidated Group with Lenders and their Affiliates | |||||
X.
|
Xxxxxxxxxx of (IA9 + IB3) − IC | $ | ||||
E.
|
Consolidated EBITDA | |||||
1. Consolidated Net Income
|
$ | |||||
(a) Net income (or loss) for the
Consolidated Group determined in accordance with GAAP
|
$ | |||||
(b) Extraordinary gains or losses
and related tax effects
|
$ |
44
(c) Gains and losses from
discontinued operations and related tax effects
|
$ | |||||
(d) Consolidated Net Income (sum of
IE1a − (IE1b + IE1c))
|
$ | |||||
2. To the extent deducted in determining net income,
|
$ | |||||
(a) Consolidated Interest Expense
(i.e. all interest expense, including the amortization of debt
discount and premium, the interest component under Capital
Leases and the implied interest component under Securitization
Transactions, determined in accordance with GAAP)
|
$ | |||||
(b) Tax expense based on income
|
$ | |||||
(c) Depreciation, amortization and
other non-cash charges (excluding restructuring charges which do
not initially involve a cash payment but as for which there will
be a subsequent cash payment)
|
$ | |||||
(d) Up to $50 million in
restructuing charges that will be paid in cash taken from the
Closing Date through December 31, 2006
|
$ | |||||
(e) Pro Forma Effect
|
||||||
(i) Acquisitions | $ | |||||
(ii) Dispositions | $ | |||||
(iii) Pro Forma Effect (IE2ei + IE2eii); provided, where the aggregate consideration paid or payable by any member of the Consolidated Group in connection with such Disposition or Acquisition is reasonably expected (taking the amount of cash and Cash Equivalents and the fair market value of any non-cash consideration paid or payable and the amount of debt assumed, as reasonably determined by FMCAG) to be $50 million or less, FMCAG may elect whether or not to make the adjustments otherwise required. | $ | |||||
(f) Sum of IE2a + IE2b + IE2c + IE2d + IE2e | $ | |||||
3. Consolidated EBITDA (sum of IE1d + IE2f) | $ | |||||
Consolidated Leverage Ratio (ID / IE3)
|
:1.0 | |||||
Maximum permitted for such quarter
|
:1.0 | |||||
A.
|
Consolidated EBITDAR | |||||
1. Consolidated EBITDA (line IE3) | $ | |||||
2. Rent expense under operating leases | $ | |||||
3. Pro Forma Effect | ||||||
(a) Acquisitions | $ | |||||
(b) Dispositions | $ | |||||
(c) Pro Forma Effect (IIA3a +
IIA3b); provided, where the aggregate consideration paid
or payable by any member of the Consolidated Group in connection
with such Disposition or Acquisition is reasonably expected
(taking the amount of cash and Cash Equivalents and the fair
market value of any non-cash consideration paid or payable and
the amount of debt assumed, as reasonably determined by FMCAG)
to be $50 million or less, FMCAG may elect whether or not to
make the adjustments otherwise required.
|
$ | |||||
4. Consolidated EBITDAR (sum of IIA1 + IIA2 + IIA3(c)) | $ | |||||
B.
|
Consolidated Fixed Charges | |||||
1. Consolidated Interest Expense (line IE2(a)) | $ | |||||
2. Rent expense under operating leases | $ |
45
3. Scheduled maturities of Consolidated Funded Debt (excluding scheduled maturities and amortization of the AG Debt and the Schuldscheindarlehen (and any replacement or refinancing thereof), and schedule maturities and amortization, including the final bullet payment at maturity, during the period from one year from the final maturity date thereof in the case of the EIB Loan, the Trust Preferred Securities and the Loans under the Credit Agreement) paid in the applicable period (provided that refinancings and extensions shall not be considered payments or repayments for purposes hereof) | $ | |||||
4. Without duplication, Restricted Payments made by FMCAG and payments by members of the Consolidated Group on any Subordinated Debt (other than the AG Debt) and Trust Preferred Securities | $ | |||||
5. Cash tax payments based on income | $ | |||||
6. Pro Forma Effect | ||||||
(a) Acquisitions | $ | |||||
(b) Dispositions | $ | |||||
(c) Pro Forma Effect (IIB6a +
IIB6b); provided, where the aggregate consideration paid
or payable by any member of the Consolidated Group in connection
with such Disposition or Acquisition is reasonably expected
(taking the amount of cash and Cash Equivalents and the fair
market value of any non-cash consideration paid or payable and
the amount of debt assumed, as reasonably determined by FMCAG)
to be $50 million or less, FMCAG may elect whether or not to
make the adjustments otherwise required.
|
$ | |||||
7. Sum of IIB1 + IIB2 + IIB3 + IIB4 + IIB5 + IB6 | $ | |||||
8. Amounts paid as a result of the audit of the German tax liability of FMCAG in respect of deductions taken in respect of the writing down of FMCAG’s investment in certain subsidiaries for German tax purposes only as of December 31, 1997, to the extent accrued as of or before December 31, 2002, adjusted for currency fluctuations, and interest thereon | $ | |||||
9. Payments made in connection with non-recurring charges taken during the year ending December 31, 2001 by members of the Consoldiated Group in an aggregate amount not to exceed $258 million with respect to: | ||||||
(a) Claims of FMCAG or any of its
Subsidiaries against WRG-Conn or its Affiliates, successors or
assigns relating to the Reorganization or arising from the
Reorganization Documents
|
$ | |||||
(b) Other costs relating directly
or indirectly, or arising from, the Reorganization or the
conduct of the business of FMCH or to its Subsidiaries before
the consummation of the Reorganization, in each case, together
with related costs and expenses
|
$ | |||||
(c) Sum of IB9a +IB9b
|
$ | |||||
10. Consolidated Fixed Charges (sum of IIB7 − (IIB8 + IIB9c) | $ | |||||
Consolidated Fixed Charge Coverage Ratio (IIA4 / IIB10)
|
:1.0 | |||||
Minimum permitted for such fiscal quarter
|
:1.0 | |||||
III. Section 8.11(c) — Consolidated Capital Expenditures: | ||||||
A.
|
All cash expenditures that, in accordance with GAAP, are or should be included in addition to property, plant and equipment and similar items reflected in the consolidated statement of cash flows for such period | $ | ||||
B.
|
Expenditures of proceeds of insurance settlements, condemnation awards, and other settlements in respect of lost, destroyed, damaged or condemned assets, equipment or other property to the extent such expenditures are made to replace or repair such lost, destroyed, damaged, or condemned assets, equipment or other property or otherwise to acquire assets or properties useful in the business of the members of the Consolidated Group | $ |
46
C.
|
Expenditures made on reinvestment of proceeds from Dispositions within the reinvestment period under Section 2.06(b)(ii) | $ | ||||
D.
|
Expenditures made in connection with a Permitted Acquisition | $ | ||||
Consolidated Capital Expenditures (IIIA − (IIIB + IIIC + IIID)) | $ | |||||
Maximum permitted in the applicable fiscal year | $ | |||||
OTHER COVENANTS:
|
||||||
IV. Section 8.01 — Indebtedness: | ||||||
A.
|
Section 8.01(e): Indebtedness under capital leases, Synthetic Lease Obligations and purchase money obligations incurred to provide all or a portion of the purchase price (or cost of construction or acquisition), in each case, for capital assets and refinancings, refundings, renewals or extensions thereof, provided that (i) such Indebtedness when incurred shall not exceed the purchase price or cost of construction of such asset, (ii) no such Indebtedness shall be refinanced for a principal amount in excess of the principal balance outstanding thereon at the time of such refinancing, and (iii) for the Consolidated Group taken as a whole, the total amount of all such Indebtedness incurred after the Closing Date plus the Attributed Principal Amount of Sale and Leaseback Transactions entered into after the Closing Date that are not otherwise included in such Indebtedness shall not exceed $250 million in the aggregate at any time | $ | ||||
B.
|
Section 8.01(f): Indebtedness and obligations under Permitted Receivables Financings, provided that the Attributed Principal Amount of all such Permitted Receivables Financings shall not exceed $1,000 million in the aggregate at any time | $ | ||||
C.
|
Section 8.01(g): senior Indebtedness of FMCAG and its Subsidiaries in an aggregate principal amount at any time outstanding of up to: (i) $1,000 million (or, to the extent that any such Indebtedness is denominated in Euros, and not counted in the amount included in clause (ii) below, the Dollar Equavalent thereof), plus (ii) an additional amount of €750 million (or, to the extent that any such Indebtedness is denominated in Dollars, and not counted in the amount included in clause (i) above, the Euro Equivalent thereof) | $ | ||||
D.
|
Section 8.01(h): senior Indebtedness of FMCAG and its Subsidaries incurred in connection with (i) repayment of the Trust Preferred Subdebt maturing 2011, and (ii) the payment or repayment of all or any portion of the Tranch B Term Loan, provided that, in either such case, such idebtedness is incurred within a twelve (12) month period beginning six (6) months before and ending six (6) months after the maturity date thereof or the date of such payment or prepayment, respectively | $ | ||||
E.
|
Section 8.01(k): Indebtedness of FMCAG and its Subsidiaries owing to Fresenius AG and any of its Subsidiaries (other than FMCAG and its Subsidiaires) in an aggregate principal amount of such AG Debt not to exceed $400 million at any time outstanding | $ | ||||
V. Section 8.02 — Liens: | ||||||
A.
|
Section 8.02(q): Liens created or deemed to exist by the establishment of trusts for the purpose of satisfying (i) Governmental Reimbursement Program Costs and (ii) other actions or claims pertaining to the same or related matters or other Medical Reimbursement Programs, provided in each case that (A) adequate reserves for such claims or actions have established and (B) contributions to such trusts in respect of such actions or claims shall not exceed $60 million at any time | $ | ||||
B.
|
Section 8.02(s): Liens other than those referred to in other subsections of Section 8.02, provided that (i) the aggregate amount of all Indebtedness secured thereby does not at any time exceed an amount equal to five percent (5%) of Consolidated Net Tangible Assets and (ii) the Liens does not cover or extend to any of the collateral pledged to secure the Obligations hereunder | $ |
47
VI. Section 8.03 — Investments: | ||||||
A.
|
Section 8.03(g): Loans to employees, directors or officers in connection with the award of convertible bonds under a stock incentive plan, stock option plan or other equity-based compensation plan or arrangement in an aggregate amount not to exceed $20 million (net of Indebtedness owing by members of the Consolidated Group to such employees, directors or officers under convertible bonds) in the aggregate at any time outstanding | $ | ||||
B.
|
Section 8.03(h): Other advances or loans to directors, officers, employees or agents not to exceed $10 million in the aggregate at any one time outstanding | $ | ||||
C.
|
Section 8.03(i): Advances or loans to customers or suppliers that do not exceed $100 million in the aggregate at any one time outstanding | $ | ||||
D.
|
Section 8.03(o): Investments by FMCAG and its Subsidiaries in and to members of the Consolidated Group that are not otherwise permitted under subsections (l), (m) or (n) of Section 8.03 in an aggregate amount outstanding at any time (excluding those Investments permitted under subsections (d), (e) or (n) of Section 8.03 not to exceed 12% of consolidated total assets of the Consolidated Group, provided that where the Investment is a loan or advance, there shall be no contractual restriction or limitation on the repayment of such indebtedness | $ | ||||
E.
|
Section 8.03(p): Investments by FMCAG and its Subsidiaries in and to joint ventures or other entities in which FMCAG, directly or indirectly, owns less than a majority of the Capital Stock with ordinary voting power of such venture or entity; provided that (i) the aggregate principal amount of all such Investments under Section 8.03(p), shall not exceed $450 million at any time, and (ii) where the Investment is a loan or advance, there shall be no contractual restriction or limitation on the repayment of any such indebtedness | $ | ||||
F.
|
Section 8.03(q): Loans and advances by FMCAG and its Subsidiaries in Fresenius AG in an aggregate principal amount not to exceed $200 million, provided that (i) where Fresenius AG shall not own the requisite Capital Stock in FMCAG to allow it to provide consolidated financial statements with the Consolidated Group under GAAP, then the aggregate principal amount of such loans and advances shall not exceed $100 million and (ii) there shall be no contractual restriction or limitation on the repayment of any such indebtedness | $ | ||||
G.
|
Section 8.03(s): Other loans, advances or investments of a nature not contemplated in the other subsections of Section 8.03 in an amount not to exceed $50 million in the aggregate at any time outstanding | $ | ||||
VII. Section 8.05 — Dispositions: | ||||||
A.
|
Section 8.05(h): Dispositions not otherwise permitted under Section 8.05, provided that (i) the aggregate book value of property so sold or otherwise disposed of under Section 8.05(h) in any given fiscal year shall not exceed an amount equal to (A) for fiscal year 2006, 7.5% of Consolidated Net Worth as of December 31, 2005 and (B) for fiscal year 2007 and each fiscal year thereafter, 5% of Consolidated Net Worth as of the end of the fiscal year immediately preceding the date of determination, (ii) no Default or Event of Default shall then exist or would result therefrom after giving effect thereto on a Pro Forma Basis, (iii) at least 70% of the consideration received in connection with such Disposition shall be in the form of cash or Cash Equivalents and (iv) the Net Cash Proceeds therefrom shall be applied in accordance with the provisions of Section 2.06(c) | $ | ||||
VII. Section 8.06 — Restricted Payments: | ||||||
A.
|
Section 8.06: Restricted Payments (made in the applicable calendar year) permitted under Section 8.06, provided that (a) no Default or Event of Default shall exist after giving effect thereto on a Pro Forma Basis and (b) the aggregate amount of Restricted Payments in any calendar year shall not in any event exceed the amount set out in Schedule 8.06 | $ | ||||
Maximum permitted in applicable calendar year | $ |
48